

Open Commentary

Pathology's New Role: Defining Disease Process and Protective Responses

George Perry¹, Rudy J. Castellani², Paula I. Moreira³, Hyoung-gon Lee⁴, Xiongwei Zhu⁴ and Mark A. Smith⁴

¹College of Sciences, University of Texas at San Antonio, San Antonio, Texas, USA; ²Department of Pathology, University of Maryland, Baltimore, Maryland, USA; ³Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal; ⁴Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA

Received 3 August 2007; Accepted 6 August 2007; Available online 1 January 2008

Since inception, pathology has served as the indispensable link between basic science and clinical disease, encompassing the defining of disease processes and mechanisms through observation of structural alterations, as well as hypothesis-driven experimentation. The careful study of pathology has delivered an understanding of disease sufficient to guide effective treatment, and recognize ineffective treatment, so consequential to man's enhanced life expectancy in the past century. This paradigm has been particularly successful in providing insights for treatment of acute diseases; however, in the setting of chronic disease, where the relationship between basic pathology (typically end-stage) and pathophysiology is often misinterpreted, progress towards effective therapy has been slow, at best [1].

Here we consider the slow progress made in effectively understanding and healing Alzheimer disease (AD) by some of the most talented scientists of our time. At the root of the issue is the role of the pathologist, who may, in the setting of chronic diseases such as AD, assign too literal a meaning to the basic pathology. The pathologists' fascination with lesions, and in particular, lesions that can be visualized – in the case of AD, the senile plaque and neurofibrillary tangle – has proven a powerful and distracting a priori bias in his assessment of pathophysiology [1, 2].

Why is this distinction so important? The medicine-pathology partnership has made the most headway with acute disease (e.g., coronary artery thrombosis and myocardial infarction), where the body responds quickly and directly to a process that if not addressed rapidly leads to major morbidity and mortality. The structural changes of the disease are linked to processes at disequilibrium. In contrast, the pathological changes of AD develop over years, and it remains an open question whether such changes mark a movement toward health, i.e. an adaptive response to a chronic process, or death. Yet, studies addressing the pathogenesis of AD are dominated by the latter construct, something more akin to an acute infection than an age-related neurodegeneration, suggesting that removal of the microscopic lesion (infectious agent by analogy) will restore health [3, 4]. Such concrete thinking, we believe, represents a fundamental misconception of the relationship between pathology and chronic disease, one that has been propagated over the decades as scientists persevere on the latest technologies rather than the clinico-pathological entities themselves. As such, a fundamental re-organization of the thought processes surrounding the pathology of chronic diseases is paramount, and a more open-minded view of pathology by pathologists themselves, we believe, is necessary to fulfill the ultimate goal of providing useful

Table 1 Technological advance and scientific discovery in AD

Technology	Discovery	References
Histological Stains	Senile plaques and neurofibrillary tangles	Alzheimer A [5]
Electron Microscopy	Amyloid fibers and paired helical filaments	Terry RD <i>et al</i> [15]
Immunohistochemistry	Linkage to the cytoskeleton	Iqbal K <i>et al</i> [16], Glenner GG <i>et al</i> [17], Perry G <i>et al</i> [18]
Protein Chemistry	Amyloid- β and tau	Glenner GG <i>et al</i> [19], Lee VM <i>et al</i> [20]
Molecular Genetics	Amyloid- β protein precursor, presenilin, apolipoprotein E	Strittmatter WJ <i>et al</i> [21], Goate AM [22], George-Hyslop PS <i>et al</i> [23]
Biophysics	Oligomers	Lacor PN <i>et al</i> [24]

information that would guide treatment efforts.

Last year marked the centennial of the clinical pathological discovery of AD, a dementia characterized by two pathological lesions [5]. Throughout this time, up to the present, the technology of the day continues to attempt to understand AD pathogenesis (**Table 1**). With each successive wave of technology, precision has increased, but the target – the pathological lesions or their surrogates – has remained essentially unchanged for those 100 years.

Even the hope of unbiased analysis through molecular genetics has disclosed genes that have all been related to AD through the pathology. Such a focus is not surprising, since pathological lesions have been effective avenues to therapeutics for over two centuries. Unfortunately, focusing on AD pathogenesis through the narrow prism of “lesion = disease,” has not led to a significant therapeutic advances [6]. Indeed, the most direct test of the pathology hypothesis, vaccine therapy, has led to pathology reversal at the cost of increased morbidity and mortality with no cognitive benefits [4]. This contradicted the prediction based on experimental models, where removal of amyloid- β (A β) or tau accumulation from genetically engineered animals effectively treats cognitive impairment and neuronal death. However, distinct from AD, these models are conditions produced by using an agent or gene to disturb normal metabolism; therefore, it might not be surprising that use of agents to remove/reverse the abnormal brings the system to normal. In this sense the models are much like infections, acute or genetic conditions where the linkage between pathology and mechanism is direct. Simple removal/reversal of the pathogen reverses disease.

AD fails the definition of a direct linkage between “pathology” and mechanism. Considering the pathological changes as primary may be highly analogous to consider the same for the inflammation of infection. Aspirin or steroids can modulate the inflammation, but not reverse the disease which requires eradication of the infectious agent. In AD and many other chronic diseases, we live with pathology for decades. Even more important, the pathology of AD is found to a similar extent in many of the normal aged [7]. Rather than viewing the lesions of AD as the traditional linkage of pathology and mechanism, they should instead be viewed as adaptive responses necessary for maintaining brain function in the face of earlier changes, e.g., oxidative stress, cell cycle reentry, and mitochondrial abnormalities [8-11]. In this light, removal of AD lesions could exacerbate the progression of disease by not protecting the brain from the primary, as yet unknown agent. In contrast, in cellular models and transgenic mice, A β is produced through exogenous intervention rather than through physiological response, and, as such, does not model the normal host response to chronic disease that should be required for any model of chronic disease to be considered relevant.

Genetic analysis has been used as the primary support for A β role in AD [12]. Numerous mutations in amyloid- β protein precursor (A β PP) and presenilin linked to AD modulate A β metabolism leading to increased A β 1-42. Not emphasized is that absolute A β levels decrease with these mutations [13, 14]. Further, if viewed as a critical response to the unidentified cause of AD, A β alteration by mutations could be responsible for AD through abnormalities in the physiological response, as would therapeutics that alter critical physiological responses.

Instead of arguing that we are entering a post-pathology era, the complexity of responses in chronic conditions requires broader understanding of pathophysiology where the normal function of gene products is on-going as diseases develop. Without that understanding, the pathologist will continue to search for structural alternations and reflexively consider them maladaptive, without fully considering the body's responses and potential adaptive structural alternations that develop over decades. On the other hand, the thoughtful pathologist who maintains his priorities would continue to be in a unique position at the interface between basic science and clinical disease, and continue to contribute to these insights through careful understanding of both the strengths and limitations of the pathological basis of disease.

Please address all correspondences to George Perry, PhD, College of Sciences, University of Texas at San Antonio, One UTSA Circle, San Antonio, Texas 78249, USA. Tel: 210-458-4450; Fax: 210-458-4445; Email: george.perry@utsa.edu

References

- [1] Castellani RJ, Lee HG, Zhu X, Nunomura A, Perry G and Smith MA. Neuropathology of Alzheimer disease: pathognomonic but not pathogenic. *Acta Neuropathol (Berl)* 2006; 111:503-509.
- [2] Castellani RJ, Zhu X, Lee HG, Moreira PI, Perry G and Smith MA. Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees? *Expert Rev Neurother* 2007;7:473-485.
- [3] Perry G, Nunomura A, Raina AK and Smith MA. Amyloid-beta junkies. *Lancet* 2000;355:757.
- [4] Smith MA, Atwood CS, Joseph JA and Perry G. Predicting the failure of amyloid-beta vaccine. *Lancet* 2002;359:1864-1865.
- [5] Alzheimer A. Über einen eigenartigen schweren Krankheitsprozess der Hirnrinde. *Zentralblatt für Nervenkrankheiten* 1906;25:1134.
- [6] Lee HG, Zhu X, Castellani RJ, Nunomura A, Perry G and Smith MA. Amyloid-beta in Alzheimer disease: the null versus the alternate hypotheses. *J Pharmacol Exp Ther* 2007;321:823-829.
- [7] Davis DG, Schmitt FA, Wekstein DR and Markesbery WR. Alzheimer neuropathologic alterations in aged cognitively normal subjects. *J Neuropathol Exp Neurol* 1999;58:376-388.
- [8] McShea A, Harris PL, Webster KR, Wahl AF and Smith MA. Abnormal expression of the cell cycle regulators P16 and CDK4 in Alzheimer's disease. *Am J Pathol* 1997;150:1933-1939.
- [9] Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, Johnson AB, Kress Y, Vinters HV, Tabaton M, Shimohama S, Cash AD, Siedlak SL, Harris PL, Jones PK, Petersen RB, Perry G and Smith MA. Mitochondrial abnormalities in Alzheimer's disease. *J Neurosci* 2001;21:3017-3023.
- [10] Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB and Smith MA. Oxidative damage is the earliest event in Alzheimer disease. *J Neuropathol Exp Neurol* 2001;60:759-767.
- [11] Smith MA, Casadesus G, Joseph JA and Perry G. Amyloid-beta and tau serve antioxidant functions in the aging and Alzheimer brain. *Free Radic Biol Med* 2002;33:1194-1199.
- [12] Hardy J and Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. *Science* 2002; 297:353-356.
- [13] Bentahir M, Nyabi O, Verhamme J, Tolia A, Horre K, Wiltfang J, Esselmann H and De Strooper B. Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. *J Neurochem* 2006;96:732-742.
- [14] Shioi J, Georgakopoulos A, Mehta P, Kouchi Z, Litterst CM, Baki L and Robakis NK. FAD mutants unable to increase neurotoxic Abeta 42 suggest that mutation effects on neurodegeneration may be independent of effects on Abeta. *J Neurochem* 2007;101:674-681.
- [15] Terry RD, Gonatas NK and Weiss M. The ultrastructure of the cerebral cortex in Alzheimer's disease. *Trans Am Neurol Assoc* 1964;89:12.
- [16] Iqbal K, Grundke-Iqbal I, Merz PA and Wisniewski HM. Alzheimer Neurofibrillary tangle: morphology and biochemistry. *Exp Brain Res* 1982;Suppl 5:10-14.
- [17] Glenner GG, Wong CW, Quaranta V and Eanes ED. The amyloid deposits in Alzheimer's disease: their nature and pathogenesis. *Appl Pathol* 1984;2:357-369.
- [18] Perry G, Rizzuto N, Autilio-Gambetti L and Gambetti P. Paired helical filaments from Alzheimer disease patients contain cytoskeletal components. *Proc Natl Acad Sci USA* 1985; 82:3916-3920.
- [19] Glenner GG and Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. *Biochem Biophys Res Commun* 1984;120:885-890.
- [20] Lee VM, Balin BJ, Otvos L, Jr. and Trojanowski JQ. A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. *Science* 1991;251:675-678.
- [21] Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS and Roses AD. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial

Perry *et al*/Comment on the New Role of Pathology

- Alzheimer disease. *Proc Natl Acad Sci USA* 1993;90:1977-1981.
- [22] Goate AM. Molecular genetics of Alzheimer's disease. *Geriatrics* 1997; 52 Suppl 2:S9-S12.
- [23] George-Hyslop PS and Rossor M. Alzheimer's disease. Unravelling the disease process. *Lancet* 2001;358 Suppl:S1.
- [24] Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, Viola KL and Klein WL. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. *J Neurosci* 2007;27:796-807.